血小板内皮聚集受体1基因分型和DNA甲基化对接受氯吡格雷治疗的复发性缺血性卒中患者血小板反应性的影响。
Impact of platelet endothelial aggregation receptor 1 genotypes and DNA methylation on platelet reactivity in patients with recurrent ischemic stroke treated with clopidogrel.
作者信息
Yang Jiahui, Bao Zhengjun, Hu Guoyu, Luo Xiaopeng, Zhao Zhen
机构信息
Department of Neurology, Zhuzhou Hospital Afliated to Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.
Department of Hematology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.
出版信息
Arch Med Sci. 2023 Feb 16;19(2):518-522. doi: 10.5114/aoms/159180. eCollection 2023.
INTRODUCTION
The aim of this study is to investigate the role of genetic variation and DNA methylation of rs12041331 in high on-treatment platelet reactivity (HPR) and recurrent ischemic stroke (RIS).
METHODS
Genotype, methylation, and mRNA of were detected in patients with cerebral ischemia, for the analysis of the effect of on HPR and RIS.
RESULTS
The major G allele of rs12041331 was associated with hypermethylation, which was associated with HPR. This link was not observed for RIS.
CONCLUSIONS
The genetic polymorphism and DNA methylation may be among the genetic factors affecting HPR. The correlation between and RIS needs to be studied further.
引言
本研究旨在探讨rs12041331的基因变异和DNA甲基化在治疗中高血小板反应性（HPR）和复发性缺血性卒中（RIS）中的作用。
方法
检测脑缺血患者的基因型、甲基化和mRNA，以分析其对HPR和RIS的影响。
结果
rs12041331的主要G等位基因与高甲基化相关，而高甲基化与HPR相关。未观察到该关联与RIS有关。
结论
基因多态性和DNA甲基化可能是影响HPR的遗传因素之一。其与RIS之间的相关性有待进一步研究。
Zotero 插件